Titre
Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Auteur(s)
Herrera, S.
Auteure/Auteur
Bonelo, A.
Auteure/Auteur
Perlaza, B. L.
Auteure/Auteur
Fernandez, O. L.
Auteure/Auteur
Victoria, L.
Auteure/Auteur
Lenis, A. M.
Auteure/Auteur
Soto, L.
Auteure/Auteur
Hurtado, H.
Auteure/Auteur
Acuna, L. M.
Auteure/Auteur
Velez, J. D.
Auteure/Auteur
Palacios, R.
Auteure/Auteur
Chen-Mok, M.
Auteure/Auteur
Corradin, G.
Auteure/Auteur
Arevalo-Herrera, M.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
0002-9637
Statut éditorial
Publié
Date de publication
2005-11
Volume
73
Numéro
5 Suppl
Première page
3
Dernière page/numéro d’article
9
Notes
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't --- Old month value: Nov
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't --- Old month value: Nov
Résumé
Substantial experimental evidence indicates that the Plasmodium circumsporozoite (CS) protein has great potential as a vaccine candidate. We tested the safety and immunogenicity of vaccines composed of P. vivax CS-derived synthetic peptides. Sixty-nine healthy, malaria-naive volunteers were randomized to receive three injections of placebo or synthetic proteins N, R, or C (10, 30, or 100 microg/dose) in a double-blinded fashion. Vaccines were well tolerated and no serious adverse events were observed. Peptides N and R elicited humoral responses at all doses; peptide C elicicted these responses only at doses of 30 and 100 microg. The N peptide at a dose of 100 microg elicited the greatest antibody response. Antibodies to the three peptides recognized P. vivax sporozoites in an immunofluorescent antibody test. Peripheral blood mononuclear cells from most immunized volunteers also produced interferon-gamma upon peptide in vitro stimulation. These vaccines appear safe, well tolerated, and immunogenic in malaria-naive volunteers. Further optimization and development of this vaccine is being attempted to conduct phase II clinical trials.
Sujets
PID Serval
serval:BIB_DBCADD330106
PMID
Date de création
2008-01-24T13:55:34.232Z
Date de création dans IRIS
2025-05-21T05:10:10Z